AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...

The Canadian biotechnology firm Bionxt Solutions has reported encouraging preclinical results for its proprietary drug delivery system. The company’s oral thin film (ODF) formulation of Cladribin, an ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...

The centre in Canterbury wants to bring specialist therapy closer to home for more people in Kent.

Revenue was largely in line with analyst expectations as Roche turns its attention to a diverse pipeline.

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic ...

By Ludwig Burger FRANKFURT, Jan 29 (Reuters) - Roche's adjusted operating income rose by a lower-than-expected 5% in 2025 as ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive ...

Roche (RHHBY) stock dips after 2025 results: sales, pharma & diagnostics growth, FX headwinds, and 2026 outlook.